Incretin mimetics have demonstrated safety and efficacy in advanced kidney disease, however multiple studies have shown that use of GLP1-RA have shown improvements in glycemic control, body weight reductions, improved beta cell function, and decreased incidence hypoglycemia as compared to DPP4i in a general diabetes population26–31, effects which might explain the reduction of acute healthcare utilization observed in this study of patients with CKD treated with GLP1-RA as compared to DPP4i. This evidence concerns the gene GCG and kidney disorder.